On March 30, 2026, Aldeyra Therapeutics Inc. was sued for violations of the federal securities laws in the United States District Court for the District of Massachusetts on behalf of investors who purchased or otherwise
acquired publicly traded Aldeyra securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.